



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-I-032**

You asked:

For information in relation to medication use over a 3 month period.

We have provided information below for the period June-Aug 2022

1. How many patients were treated by your health board (for any condition) in the last 3 months with the following drugs:

Adalimumab (Amgevita)	64
Adalimumab (Humira)	7
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	24

2. How many patients were treated for Hidradenitis Suppurativa in the last 3 months with the following drugs:

Adalimumab (Humira)	<5
Adalimumab Biosimilar	29
Infliximab (Remicade)	0
Infliximab Biosimilar	<5
Ustekinumab (Stelara)	0
Secukinumab (Cosentyx)	0

3. How many patients were treated for Psoriasis in the last 3 months with the following:

Please note that a large number of patients will be treated in primary care for this indication – patient numbers below reflect patients directly issued these medications within secondary care in this three month period under the care of dermatology (no further analysis of clinical indication available).

Ciclosporin	7
Methotrexate – any form and strength	116
Methotrexate injections 15mg and above	18



Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

